Accessibility Menu
 
Aurinia Pharmaceuticals logo

Aurinia Pharmaceuticals

(NASDAQ) AUPH

Current Price$15.77
Market Cap$2.00B
Since IPO (2012)+659%
5 Year+21%
1 Year+93%
1 Month-3%

Aurinia Pharmaceuticals Financials at a Glance

Market Cap

$2.00B

Revenue (TTM)

$298.30M

Net Income (TTM)

$298.21M

EPS (TTM)

$2.16

P/E Ratio

7.19

Dividend

$0.00

Beta (Volatility)

1.17 (Average)

Price

$15.77

Volume

143,647.474

Open

$15.35

Previous Close

$15.55

Daily Range

$15.28 - $15.66

52-Week Range

$7.29 - $16.88

AUPH: Motley Fool Moneyball Superscore

66

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Aurinia Pharmaceuticals

Industry

Biotechnology

Employees

128

CEO

Kevin C. Tang

Headquarters

Edmonton, BC V8Z 7X8, CA

AUPH Financials

Key Financial Metrics (TTM)

Gross Margin

90%

Operating Margin

42%

Net Income Margin

100%

Return on Equity

65%

Return on Capital

20%

Return on Assets

41%

Earnings Yield

13.91%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.00B

Shares Outstanding

128.60M

Volume

143.65K

Avg. Volume

1.18M

Financials (TTM)

Gross Profit

$250.39M

Operating Income

$104.91M

EBITDA

$127.76M

Operating Cash Flow

$135.66M

Capital Expenditure

$252.00K

Free Cash Flow

$135.41M

Cash & ST Invst.

$398.00M

Total Debt

$74.81M

Aurinia Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$77.70M

+24.4%

Gross Profit

$71.20M

+32.1%

Gross Margin

91.63%

N/A

Market Cap

$2.00B

N/A

Market Cap/Employee

$15.38M

N/A

Employees

130

N/A

Net Income

$34.35M

+47.2%

EBITDA

$49.75M

+64.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Net Cash

$310.14M

+32.0%

Accounts Receivable

$49.17M

+21.9%

Inventory

$46.41M

+0.5%

Long Term Debt

$50.50M

-19.0%

Short Term Debt

$18.14M

+16.7%

Return on Assets

41.19%

N/A

Return on Invested Capital

19.53%

N/A

Free Cash Flow

$32.52M

+2434.8%

Operating Cash Flow

$32.56M

+2404.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CLDXCelldex Therapeutics, Inc.
$30.93+2.60%
STOKStoke Therapeutics, Inc.
$30.08+0.42%
HRMYHarmony Biosciences Holdings, Inc.
$31.15+2.33%
VERAVera Therapeutics, Inc.
$34.29+3.13%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$14.20+0.03%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$43.80-0.01%
TET1 Energy Inc.
$7.87+0.14%
INFYInfosys
$12.32-0.03%

Questions About AUPH

What is the current price of Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals is trading at $15.60 per share.

What is the 52-week range for Aurinia Pharmaceuticals?

Over the past 52 weeks, Aurinia Pharmaceuticals has traded between $7.29 and $16.88.

How much debt does Aurinia Pharmaceuticals have?

As of the most recent reporting period, Aurinia Pharmaceuticals reported total debt of $68.64M.

How much cash does Aurinia Pharmaceuticals have on hand?

Aurinia Pharmaceuticals reported $41.01M in cash and cash equivalents in its most recent financial results.

What is Aurinia Pharmaceuticals’s dividend yield?

Aurinia Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.